Tae Hyun Kim

Dr. Tae Hyun Kim

National Cancer Center, Goyang-si, Republic of Korea
orcid

Research Focus & Metrics

Academic Career Length

57Years (1970-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2013 in International Journal of Radiation Oncology, Biology, Physics
Verified
Journal Article
Closed access
DPDavid A. Palma
David A. Palma
SSSuresh Senan
Suresh Senan
KTKayoko Tsujino
Kayoko Tsujino
RBRobert B. Barriger
Robert B. Barriger
RRRamesh Rengan
Ramesh Rengan
GRGeorge Rodrigues
George Rodrigues

5 December 2007 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
TKTae Hyun Kim
Tae Hyun Kim
SJSeung-Yong Jeong
Seung-Yong Jeong
DCDong Hyun Choi
Dong Hyun Choi
DKDae Yong Kim
Dae Yong Kim
KJKyung Hae Jung
Kyung Hae Jung
JPJae-Gahb Park
Jae-Gahb Park

1 March 2006 in Neurobiology of Disease
Verified
Journal Article
Closed access
SHSo-Young Hwang
So-Young Hwang
JJJae-Seob Jung
Jae-Seob Jung
TKTae-Hyun Kim
Tae-Hyun Kim
SLSoo-Jeong Lim
Soo-Jeong Lim
EOEok-Soo Oh
Eok-Soo Oh
IHInn-Oc Han
Inn-Oc Han

1 March 2021 in Journal of Hepatology
Verified
Journal Article
Open access
TKTae Hyun Kim
Tae Hyun Kim
YKYoung Hwan Koh
Young Hwan Koh
BKBo Hyun Kim
Bo Hyun Kim
MKMin Ju Kim
Min Ju Kim
JLJu Hee Lee
Ju Hee Lee
JPJoong-Won Park
Joong-Won Park
Proton beam radiotherapy (PBT) has recently been applied to treat hepatocellular carcinoma (HCC); however, there is no randomized controlled trial-based evidence on its safety and efficacy. We compared the outcomes of PBT and radiofrequency ablation (RFA) in patients with recurrent/residual HCC (rHCC) in a phase III non-inferiority trial. Patients with rHCC (size <3 cm, number ≤2) were randomly assigned to receive PBT or RFA according to Child-Pugh score and tumor stage. After randomization, if the assigned treatment was technically infeasible, crossover was allowed. The primary endpoint was 2-year local progression-free survival (LPFS), with a non-inferiority margin of 15% in the per-protocol (PP) population; a complementary analysis was performed in the intention-to-treat (ITT) population (NCT01963429). The ITT population comprised 144 patients receiving either PBT (n = 72) or RFA (n = 72). Six patients switched from the PBT arm to the RFA arm and 19 patients switched from the RFA arm to the PBT arm. In the PP population, the 2-year LPFS rate with PBT (n = 80) vs. RFA (n = 56) was 94.8% vs. 83.9%, a difference of 10.9 percentage points (90% CI 1.8-20.0; p <0.001); in the ITT population, the 2-year LPFS rate with PBT vs. RFA was 92.8% vs. 83.2%, a difference of 9.6 percentage points (90% CI 0.7-18.4; p <0.001), meeting the criteria for non-inferiority. The 3- and 4-year LPFS rates for PBT were also non-inferior to those for RFA. The most common adverse events were radiation pneumonitis (32.5%) and decreased leukocyte counts (23.8%) for PBT and increased alanine aminotransferase levels (96.4%) and abdominal pain (30.4%) for RFA. No Grade 4 adverse events or mortality were noted. PBT showed LPFS values that were non-inferior to those for RFA; in addition, PBT was tolerable and safe. CLINICAL TRIAL NUMBER: #NCT01963429 (ClinicalTrials.gov). Radiofrequency ablation is the standard of care for patients with small hepatocellular carcinoma in whom surgery is not feasible. This study is the first phase III randomized controlled trial to evaluate the clinical outcomes of proton beam radiotherapy vs. radiofrequency ablation in patients with recurrent small HCC. Our findings show that this new technique is not inferior and can be applied safely in patients with small recurrent hepatocellular carcinoma.

28 February 2008 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
BNByung-Ho Nam
Byung-Ho Nam
SKSun Young Kim
Sun Young Kim
HHHye Sook Han
Hye Sook Han
YKYoungmee Kwon
Youngmee Kwon
KLKeun Seok Lee
Keun Seok Lee
JRJungsil Ro
Jungsil Ro
Introduction: Brain metastases (BM) occur in up to one third of patients with metastatic breast cancer (MBC), whose incidences and prognoses by breast cancer subtypes in BM have not been well delineated. Methods: Retrospective survival analyses were performed in 126 BM patients from 805 MBC patients treated at the National Cancer Center between August 2001 and April 2006, according to clinical characteristics, breast cancer subtypes, and receipt of trastuzumab. Estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth receptor-2 (HER2) statuses were tested by immunohistochemical (IHC) staining, and HER2 FISH analysis conducted for IHC 2+. Results: The proportion of HER2+/ER- (29% vs 16%) and triple-negative (37% vs 25%) tumors was higher in the 126 BM patients than those without BM. While median survival after recurrence was longer in patients with luminal A disease (median survival of luminal A vs luminal B vs HER2+/ER- vs triple-negative: p = 0.0246; 39.6 vs 27.4 vs 20.9 vs 15.5 months), survival was shorter from BM to death in luminal A and triple negatives (median survival: p = 0.0113; 4.0 vs 9.2 vs 5.0 vs 3.4 months). Receipt of trastuzumab after BM was a significant variable for survival in HER2+ patients. Multivariate analyses identified ER-negative, HER2-negative, or triple-negative, as well as older age, presence of leptomeningeal disease, and three or more extracranial disease sites, as poor prognostic factors for survival after BM. Conclusion: MBC patients who developed BM had higher proportions of triple-negative and HER2+/ER- tumor status. Triple receptor status is a useful prognostic marker for predicting survival after BM in metastatic breast cancer patients.

1 November 2013 in International Journal of Radiation Oncology, Biology, Physics
Verified
Journal Article
Closed access
DPDavid A. Palma
David A. Palma
SSSuresh Senan
Suresh Senan
COCary Oberije
Cary Oberije
JBJose Belderbos
Jose Belderbos
NDNURIA RODRIGUEZ DE DIOS
NURIA RODRIGUEZ DE DIOS
GRGeorge Rodrigues
George Rodrigues